A new trading day began on Tuesday, with CRISPR Therapeutics AG (NASDAQ: CRSP) stock price up 7.09% from the previous day of trading, before settling in for the closing price of $51.19. CRSP’s price has ranged from $30.04 to $63.68 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -25.48%. With a float of $82.79 million, this company’s outstanding shares have now reached $86.36 million.
Let’s determine the extent of company efficiency that accounts for 393 employees. In terms of profitability, gross margin is -239.71%, operating margin of -1282.72%, and the pretax margin is -1032.03%.
CRISPR Therapeutics AG (CRSP) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of CRISPR Therapeutics AG is 4.14%, while institutional ownership is 69.28%. The most recent insider transaction that took place on May 29 ’25, was worth 141,316. In this transaction Chief Medical Officer of this company sold 3,932 shares at a rate of $35.94, taking the stock ownership to the 6,068 shares. Before that another transaction happened on Mar 21 ’25, when Company’s Chief Executive Officer sold 10,031 for $41.23, making the entire transaction worth $413,578. This insider now owns 195,085 shares in total.
CRISPR Therapeutics AG (CRSP) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -25.48% per share during the next fiscal year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
Here are CRISPR Therapeutics AG’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 15.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 125.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.52, a number that is poised to hit -1.43 in the next quarter and is forecasted to reach -4.46 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
Looking closely at CRISPR Therapeutics AG (NASDAQ: CRSP), its last 5-days average volume was 2.92 million, which is a jump from its year-to-date volume of 2.39 million. As of the previous 9 days, the stock’s Stochastic %D was 87.15%.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 95.90%, which indicates a significant decrease from 97.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.79 in the past 14 days, which was higher than the 2.34 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $40.90, while its 200-day Moving Average is $43.25. However, in the short run, CRISPR Therapeutics AG’s stock first resistance to watch stands at $56.30. Second resistance stands at $57.79. The third major resistance level sits at $60.36. If the price goes on to break the first support level at $52.24, it is likely to go to the next support level at $49.67. Should the price break the second support level, the third support level stands at $48.18.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
With a market capitalization of 4.73 billion, the company has a total of 86,364K Shares Outstanding. Currently, annual sales are 37,310 K while annual income is -366,250 K. The company’s previous quarter sales were 870 K while its latest quarter income was -136,000 K.
